Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2268-2281

  Yaari Stark, Shira ^a   Shaked, Maayan ^a   Nevo Caspi, Yael ^b   Jacob Hircsh, Jasmine ^a,b   Shamir, Ron ^a   Rechavi, Gideon ^a,b   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

ATF; HO 1; Nrf 2; peIF2 ; Stress; UPR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVATING TRANSCRIPTION FACTOR 4; FARNESYLTHIOSALICYLIC ACID; HYBRID PROTEIN; INITIATION FACTOR 2ALPHA; SALIRASIB; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ELF2 PROTEIN, HUMAN; ENZYME INHIBITOR; FARNESOL; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYCN PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PERK KINASE; PROTEIN KINASE R; RAS PROTEIN; SALICYLIC ACID DERIVATIVE; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENDOPLASMIC RETICULUM STRESS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; ONCOGENE MYC; ONCOGENE RAS; PRIORITY JOURNAL; CELL PROLIFERATION; CELL STRAIN K 562; DRUG ANTAGONISM; DRUG EFFECT; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE; UNFOLDED PROTEIN RESPONSE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; EIF-2 KINASE; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; FARNESOL; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROBLASTOMA; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; SALICYLIC ACIDS; TRANSCRIPTION FACTORS; UNFOLDED PROTEIN RESPONSE;

EID: 77951226180     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25102     Document Type: Article

References (55)

1. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349:117-127 (Pubitemid 21912023)
2. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10: 147-154
3. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689 (Pubitemid 19213607)
4. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356:713-715
5. Scheffzek K, Ahmadian MR, Wittinghofer A. GTPase-activating proteins: helping hands to complement an active site. Trends Biochem Sci 1998;23:257-262 (Pubitemid 28343370)
6. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-2514
7. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G, Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005;11: 4321-4330 (Pubitemid 40825619)
8. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002;277:11617-11620
9. Bachireddy P, Bendapudi PK, Felsher DW. Getting at MYC through RAS. Clin Cancer Res 2005;11:4278-4281
10. Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B. Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 1986;233:461-464 (Pubitemid 16046305)
11. Knyazev PG, Fedorov SN, Serova OM, Pluzhnikova GF, Novikov LB, Kalinovsky VP, Seitz JF. Molecular-genetic analysis of myc and c-Ha-ras proto-oncogene alterations in human carcinoma. Haematol Blood Transfus 1987;31:469-473
12. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984;226:1335-1337 (Pubitemid 15215589)
13. Ernst TJ, Gazdar A, Ritz J, Shipp MA. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 1988;72:1163-1167 (Pubitemid 18265874)
14. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995;181:307-313
15. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 1991;51:1596-1599
16. Delgado MD, Vaque JP, Arozarena I, Lopez-Ilasaca MA, Martinez C, Crespo P, Leon J. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene 2000;19:783-790 (Pubitemid 30107709)
17. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007;67:3320-3328 (Pubitemid 46724871)
18. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002;277:37169-37175
19. Shamir R, Maron-Katz A, Tanay A, Linhart C, Steinfeld I, Sharan R, Shiloh Y, Elkon R. EXPANDER-an integrative program suite for microarray data analysis. BMC Bioinformatics 2005;6:232. (Pubitemid 41548723)
20. Sharan R, Shamir R. CLICK: a clustering algorithm with applications to gene expression analysis. Proc Int Conf Intell Syst Mol Biol 2000;8:307-316
21. Niv H, Gutman O, Henis YI, Kloog Y. Membrane interactions of a constitutively active GFP-K-Ras 4B and their role in signaling: evidence from lateral mobility studies. J Biol Chem 1999;274: 1606-1613 (Pubitemid 129507753)
22. Cohen N, Novikov I, Hardan I, Esa A, Brok-Simoni F, Amariglio N, Rechavi G, Ben-Bassat I, Trakhtenbrot L. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 2000; 123:102-108 (Pubitemid 32012492)
23. Mor A, Keren G, Kloog Y, George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol 2008;38: 1493-1502
24. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005; 65:999-1006. (Pubitemid 40216462)
25. Elkon R, Linhart C, Sharan R, Shamir R, Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res 2003;13:773-780 (Pubitemid 36621737)
26. Berkovich E, Ginsberg D. Ras induces elevation of E2F-1 mRNA levels. J Biol Chem 2001;276:42851-42856 (Pubitemid 37370961)
27. Gu Z, Kuntz-Simon G, Rommelaere J, Cornelis J. Oncogenic transformation-dependent expression of a transcription factor NF-Y subunit. Mol Carcinog 1999;24:294-299 (Pubitemid 29232650)
28. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001;20: 1383-1393 (Pubitemid 32233978)
29. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
30. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004;36: 1199-1207
31. Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/ Nrf2 signaling pathway. Int J Biochem Cell Biol 2006;38:317-332
32. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006;34:7-11.
33. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001;21:1249-1259
34. Hetz C, Bernasconi P, Fisher J, Lee AH, Bassik MC, Antonsson B, Brandt GS, Iwakoshi NN, Schinzel A, Glimcher LH, Korsmeyer SJ. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006;312:572-576
35. Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 2008;439:467-489
36. Kietzmann T, Samoylenko A, Immenschuh S. Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat hepatocytes. J Biol Chem 2003;278:17927-17936 (Pubitemid 36799399)
37. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/ reperfusion. Circ Res 1996;79:162-173 (Pubitemid 26255867)
38. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003;159: 283-300. (Pubitemid 36314943)
39. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603. (Pubitemid 36395654)
40. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 2003;23:7198-7209 (Pubitemid 37211002)
41. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999;3:169-179 (Pubitemid 29292618)
42. Keum YS, Jeong WS, Kong AN. Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 2004;555:191-202. (Pubitemid 39345404)
43. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22. (Pubitemid 37328883)
44. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005;15:R563-R574.
45. Smalley KS, Eisen TG. Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 2002;98:514-522
46. Berlanga JJ, Santoyo J, De Haro C. Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase. Eur J Biochem 1999;265: 754-762 (Pubitemid 29489008)
47. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997;17:503-524 (Pubitemid 27475916)
48. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000;5:897-904.
49. Oyadomari S, Mori M. Roles of CHOP/ GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381-389 (Pubitemid 38489416)
50. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-344 (Pubitemid 38756868)
51. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006;8:1053-1063 (Pubitemid 44473600)
52. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 2004;64:4577-4584 (Pubitemid 38856931)
53. Hsieh CH, Rau CS, Hsieh MW, Chen YC, Jeng SF, Lu TH, Chen SS. Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation. Toxicol Sci 2008;101: 112-121
54. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans,transfarnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002; 8:555-565 (Pubitemid 34193977)
55. Halaschek-Wiener J, Kloog Y, Wacheck V, Jansen B. Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol 2003;120:109-115